Alexion Pharma

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies.

Wilson Therapeutics

Synageva was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

Synageva

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals announces achievement of milestone using J-Brain Cargo® for neurodegenerative disease in research collaboration with Alexion.

JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion

Alnylam Pharmaceuticals

argenx

Blueprint Medicines

Exelixis

Genmab - ADR

Incyte

Seagen

Sarepta Therapeutics

Celgene

Horizon Pharma

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

5 Biotech Acquisition Targets To Accumulate In 2024

HYOGO, Japan--(BUSINESS WIRE)--JCR announced an agreement with Alexion for the development of novel oligonucleotide therapeutics to support targeted delivery using J-Brain Cargo®.

JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology

AstraZeneca

AstraZeneca PLC (LSE:AZN) said the US Food and Drug Administration (FDA) has responded to a request to expand the use of the drug Ultomiris by asking for a risk evaluation and mitigation strategy. In doing so, the regulator wants to ensure the benefits of the treatment outweigh the potential downsides.

AstraZeneca and Alexion working with FDA on US label expansion for Ultomiris

TEL AVIV, Israel , May 30, 2023 /PRNewswire/ -- BioLight (TASE: BOLT) is proud to report it has signed a research collaboration agreement with Alexion (AstraZeneca Rare Disease), focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases. The study, financed by Alexion and BioLight, will evaluate a screening technique (the "Technology") that analyzes components of the tear film, an outer eye surface fluid layer.

BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that the company signed a Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain Cargo.

JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease

Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022

AstraZeneca PLC (LSE:AZN) is set to pay out US$775mln to settle a patent dispute between its recently acquired rare diseases business Alexion and the Chugai Pharmaceutical Company. The litigation relates to a drug called Ultomiris, used to treat paroxysmal nocturnal hemoglobinuria and atypical haemolytic uraemic syndrome – two life-threatening conditions.

AstraZeneca to pay US$775mln to settle Alexion patent dispute

AstraZeneca PLC (LSE:AZN) said five new drugs had taken on blockbuster status last year generating over US$1bn in revenues each as delivered a strong financial performance, boosted by the US$39bn takeover of Alexion Pharmaceuticals (NASDAQ:ALXN). Total revenues for 2021 were US$37.4mln, up 41%, while core earnings rose 32% to US$5.29 per share.

AstraZeneca PLC boosted by Alexion acquisition; five newly-minted blockbusters join its medicine cabinet

AstraZeneca PLC (LSE:AZN)'s acquisition of Alexion Pharmaceuticals (NASDAQ:ALXN) Inc was the highlight of a third-quarter that saw UK companies splash out £32.8bn on acquisitions. Figures from the Office for National Statistics (ONS) show that while the three months to the end of September saw a decline in merger & acquisition (M&A) deals to 136 a month from 164 in the preceding quarter, UK companies flexed their muscle overseas a bit more, with foreign businesses acquired valued at £32.8bn, well up from £8.2bn in the preceding quarter.

AstraZeneca's takeover of Alexion the highlight of a quieter quarter for mergers & acquisitions

AstraZeneca PLC (LON:AZN) announced that Alexion's Ultomiris has been recommended for marketing authorisation in the EU for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria (PNH). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on interim results from the Phase III clinical trial in children and teens with PNH.

AstraZeneca says Alexion receives recommendation to use rare blood disorder drug in kids

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?

Bio-Techne

ALXN vs. TECH: Which Stock Is the Better Value Option?

Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year. The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing, a whopping 48% increase over the same period in 2020.

Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms

AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?

With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.

With the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?

Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.

Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study

Alexion Pharmaceuticals Inc (NASDAQ: ALXN) announced topline results from a Phase 3 study evaluating Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).  The study met its primary endpoint, with a statistically significant change in MG-ADL score from baseline through Week 26 for Ultomiris compared to placebo (-3.1 versus -1.4).

Alexion's Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder

BOSTON--(BUSINESS WIRE)--Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG).

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

Here is Why Growth Investors Should Buy Alexion (ALXN) Now

AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.

AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition

AstraZeneca PLC's (LON:AZN) expects to complete its £27.5bn acquisition of rare disease specialist Alexion Pharmaceuticals Inc next week after getting the go-ahead from UK authorities. The UK Competition and Markets Authority said this morning that it cleared the proposed deal, deciding not to refer it to a Phase 2 investigation.

AstraZeneca gets final go-ahead for £27.5bn Alexion acquisition

Britain's competition regulator said on Wednesday it has cleared AstraZeneca's $39 billion buyout of U.S.-based Alexion after it decided not to initiate a broader probe into the deal following its initial assessment.

British watchdog clears AstraZeneca's $39 billion buyout of Alexion

Alexion (ALXN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

News for Alexion Pharma Stock (ALXN)